OA12969A - Combination for the treatment of ADHD. - Google Patents

Combination for the treatment of ADHD. Download PDF

Info

Publication number
OA12969A
OA12969A OA1200500174A OA1200500174A OA12969A OA 12969 A OA12969 A OA 12969A OA 1200500174 A OA1200500174 A OA 1200500174A OA 1200500174 A OA1200500174 A OA 1200500174A OA 12969 A OA12969 A OA 12969A
Authority
OA
OAPI
Prior art keywords
azabicyclo
substituted
carboxamide
alkyl
oct
Prior art date
Application number
OA1200500174A
Other languages
English (en)
Inventor
Donn Gregory Wishka
Vincent Edward Groppi Jr
Eric Jon Jacobsen
Jason Kenneth Myers
David Walter Piotrowski
Bruce Nelsen Rogers
Daniel Patrick Walker
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of OA12969A publication Critical patent/OA12969A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal Substances (AREA)
OA1200500174A 2002-12-11 2003-11-28 Combination for the treatment of ADHD. OA12969A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
OA12969A true OA12969A (en) 2006-10-13

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200500174A OA12969A (en) 2002-12-11 2003-11-28 Combination for the treatment of ADHD.

Country Status (23)

Country Link
US (1) US20050107425A1 (pl)
EP (1) EP1572300A1 (pl)
JP (1) JP2006510663A (pl)
KR (1) KR20050085538A (pl)
CN (1) CN1735441A (pl)
AP (1) AP2005003336A0 (pl)
AU (1) AU2003283656A1 (pl)
BR (1) BR0317229A (pl)
CA (1) CA2509142A1 (pl)
CO (1) CO5700801A2 (pl)
CR (1) CR7868A (pl)
EA (1) EA200500783A1 (pl)
EC (1) ECSP055852A (pl)
HR (1) HRP20050522A2 (pl)
IS (1) IS7858A (pl)
MA (1) MA27606A1 (pl)
MX (1) MXPA05006336A (pl)
NO (1) NO20053185L (pl)
OA (1) OA12969A (pl)
PL (1) PL377552A1 (pl)
TN (1) TNSN05158A1 (pl)
WO (1) WO2004052461A1 (pl)
ZA (1) ZA200504338B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CA2681934A1 (en) * 2007-03-28 2008-10-02 High Point Pharmaceuticals, Llc 11beta-hsd1 active compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
NZ594937A (en) * 2008-02-19 2013-03-28 Adolor Corp Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
MX2011005037A (es) 2008-11-21 2011-06-16 High Point Pharmaceuticals Llc Compuestos de adamantilo benzamida.
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
MX357676B (es) 2010-05-17 2018-07-18 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
CN113164508B (zh) 2018-12-19 2025-07-08 达萨玛治疗公司 与神经保护剂组合的sarm1抑制剂
KR102629135B1 (ko) 2021-08-19 2024-01-29 단국대학교 천안캠퍼스 산학협력단 Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
US20240350471A1 (en) 2021-08-20 2024-10-24 Dankook University Cheonan Campus Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder
KR102684933B1 (ko) 2021-08-20 2024-07-16 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
ZA200504338B (en) 2006-07-26
PL377552A1 (pl) 2006-02-06
AP2005003336A0 (en) 2005-06-30
IS7858A (is) 2005-05-23
CA2509142A1 (en) 2004-06-24
MA27606A1 (fr) 2005-11-01
CN1735441A (zh) 2006-02-15
HRP20050522A2 (en) 2005-12-31
EA200500783A1 (ru) 2005-12-29
NO20053185L (no) 2005-08-17
AU2003283656A1 (en) 2004-06-30
TNSN05158A1 (fr) 2007-05-14
KR20050085538A (ko) 2005-08-29
CR7868A (es) 2005-07-08
WO2004052461A1 (en) 2004-06-24
JP2006510663A (ja) 2006-03-30
MXPA05006336A (es) 2005-08-26
CO5700801A2 (es) 2006-11-30
BR0317229A (pt) 2005-11-01
US20050107425A1 (en) 2005-05-19
NO20053185D0 (no) 2005-06-29
ECSP055852A (es) 2005-09-20
EP1572300A1 (en) 2005-09-14

Similar Documents

Publication Publication Date Title
AU2003279492A1 (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
AU2004206107A1 (en) Treatment of diseases with alpha-7 nach receptor full agonists
EP1432707B1 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US20050107425A1 (en) Treatment of attention defecit hyperactivity disorder
WO2003070732A1 (en) Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
CA2460075A1 (en) Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
JP2006506395A (ja) CNS疾患の治療のための、α7ニコチンアゴニスト活性及び5HT3アンタゴニスト活性を有する化合物
WO2004039366A1 (en) Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
CN103443075A (zh) 作为烟碱型乙酰胆碱受体调节剂的吡咯衍生物在治疗神经变性障碍,例如阿耳茨海默氏病和帕金森氏病中的用途
AU2002339957A1 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease